Australian Clinical Labs (ACL.AX) Earnings Analysis
Australian Clinical Labs (ACL.AX) next reports earnings on 2026-08-26, consensus EPS 0.11 AUD. Last quarter (2026-02-15) it missed with EPS 0.067 AUD vs 0.07333 AUD est (-8.6%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 15.00.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ACL.AX next report earnings?
| Next earnings date | 2026-08-26 |
|---|---|
| Consensus EPS estimate | 0.11 AUD |
| Revenue estimate | 0.37B |
ACL.AX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-15 | 0.067 AUD | 0.07333 AUD | -8.6% | Miss |
| 2025-02-26 | 0.05792 AUD | 0.07 AUD | -17.3% | Miss |
| 2024-08-29 | 0.09539 AUD | 0.08 AUD | +19.2% | Beat |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
ACL.AX valuation and analyst view
| Trailing P/E | 15.00 |
|---|---|
| Trailing EPS | 0.13581 AUD |
| Price / book | 2.87 |
| Dividend yield | 5.72% |
| Market cap | 0.43B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Australian Clinical Labs (ACL.AX)'s next earnings date?
Australian Clinical Labs is next scheduled to report on 2026-08-26, with a consensus EPS estimate of 0.11 AUD and revenue estimate of 0.37B.
Did ACL.AX beat earnings last quarter?
In its 2026-02-15 report, ACL.AX posted EPS of 0.067 AUD versus a 0.07333 AUD estimate — a miss of 8.6%.
What is ACL.AX's earnings track record?
Over the last 3 reported quarters with consensus data, ACL.AX beat estimates 1 times (33%).
What is ACL.AX's current P/E ratio and EPS?
ACL.AX trades at a trailing P/E of 15.00 on trailing EPS of 0.1358103026469877 AUD.
What do analysts rate ACL.AX?
ACL.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.